Portola Pharmaceuticals (NASDAQ:PTLA) Downgraded by Zacks Investment Research to "Sell"

The institutional investor held 2,800 shares of the public utilities company at the end of 2017Q3, valued at $54,000, down from 50,115 at the end of the previous reported quarter. Argentiere Capital Ag who had been investing in Nike Inc for a number of months, seems to be less bullish one the $105.51 billion market cap company. The stock increased 0.13% or $0.16 during the last trading session, reaching $119.7. Ally Financial Inc. (NYSE:ALLY) has risen 12.72% since January 12, 2017 and is uptrending. It has underperformed by 1.24% the S&P500.

Hartwell J M Limited Partnership increased its stake in Portola Pharmaceuticals (PTLA) by 148.77% based on its latest 2017Q3 regulatory filing with the SEC. KS now owns 727,812 shares of the biopharmaceutical company's stock valued at $39,324,000 after purchasing an additional 202,925 shares during the last quarter. The hedge fund held 35,450 shares of the health care company at the end of 2017Q3, valued at $1.92M, up from 14,250 at the end of the previous reported quarter. Portola Pharmaceuticals Inc now has $3.43B valuation. The stock had a trading volume of 623,664 shares, compared to its average volume of 1,030,000. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has risen 51.17% since January 14, 2017 and is uptrending. It has outperformed by 34.47% the S&P500. Finally, Zacks Investment Research raised shares of Portola Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Wednesday. Therefore 42% are positive. Oppenheimer's target price indicates a potential upside of 52.03% from the company's current price. The rating was maintained by Oppenheimer on Friday, August 4 with "Buy". Susquehanna downgraded the shares of Monday in report on Tuesday, June 27 to "Neutral" rating. The firm has "Buy" rating by TD Securities given on Thursday, September 28. The company was maintained on Monday, November 2 by Barclays Capital. The firm has "Hold" rating given on Thursday, October 15 by Topeka Capital Markets. The firm has "Hold" rating by RBC Capital Markets given on Thursday, July 20. JP Morgan reinitiated the stock with "Neutral" rating in Thursday, October 8 report. Its up 0.85, from 1.31 in 2017Q2. It is negative, as 23 investors sold Cognex Corporation shares while 135 reduced holdings. 84 funds opened positions while 244 raised stakes. Deerfield Mngmt Company invested in 0.73% or 298,545 shares. Invesco Limited holds 0.03% of its portfolio in Cognex Corporation (NASDAQ:CGNX) for 805,777 shares. Secor Cap Advsrs L P invested in 0.32% or 30,069 shares. During the same period past year, the firm earned ($1.05) earnings per share. Haverford Tru reported 11,242 shares. Motco accumulated 9,466 shares. Lord Abbett And Communications Lc has invested 0.1% in Monsanto Company (NYSE:MON). Fifth Third Retail Bank has 0.01% invested in Texas Pacific Land Trust (NYSE:TPL) for 1,775 shares. Neuberger Berman Gp Limited reported 0% stake. Utah Retirement reported 80,463 shares.

Since August 3, 2017, it had 0 insider purchases, and 7 selling transactions for $13.24 million activity. Zacks downgraded Nutrien Ltd. (NYSE:POT) on Monday, September 7 to "Sell" rating. Goldman Sachs Group, Inc.

Sphera Funds Management Ltd, which manages about $700.90M US Long portfolio, decreased its stake in Tjx Cos Inc New (NYSE:TJX) by 18,900 shares to 5,800 shares, valued at $428,000 in 2017Q3, according to the filing. It also reduced its holding in Centene Corp Del (NYSE:CNC) by 21,676 shares in the quarter, leaving it with 5,400 shares, and cut its stake in Bard C R Inc (NYSE:BCR).

Investors sentiment increased to 2.16 in Q3 2017. William Blair also issued estimates for Portola Pharmaceuticals' Q2 2018 earnings at ($1.10) EPS, Q3 2018 earnings at ($0.92) EPS, Q4 2018 earnings at ($0.56) EPS, FY2018 earnings at ($3.80) EPS, FY2019 earnings at $0.11 EPS and FY2020 earnings at $5.11 EPS.

Large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp raised its stake in shares of Portola Pharmaceuticals by 10.7% in the second quarter. Canada Pension Plan Investment Board stated it has 0% of its portfolio in Portola Pharmaceuticals, Inc. Ameritas Inv Prns Inc has invested 0.03% in Xilinx, Inc. BidaskClub upgraded shares of Portola Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Thursday, December 21st.

Portola Pharmaceuticals, Inc is a biopharmaceutical company. (NASDAQ:PTLA) for 33,456 shares. California-based Cap Sarl has invested 0.06% in Xilinx, Inc. (NASDAQ:PTLA) for 1.03 million shares. First Allied Advisory Service owns 0.02% invested in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) for 6,548 shares. Numeric Invsts Limited Liability Company reported 158,300 shares. (NASDAQ:PTLA). Sg Americas Ltd invested in 6,079 shares or 0% of the stock. Moreover, Ny State Common Retirement Fund has 0% invested in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) for 55,700 shares. Fiera invested in 0.02% or 66,535 shares. Vanguard accumulated 5.24M shares. (NASDAQ:PTLA). D E Shaw And holds 0.09% of its portfolio in Portola Pharmaceuticals, Inc. Therefore 57% are positive. Finally, Credit Suisse Group lifted their target price on Portola Pharmaceuticals from $20.00 to $29.00 and gave the stock an outperform rating in a research report on Tuesday, December 27th. The rating was maintained by Jefferies on Tuesday, August 22 with "Buy". The rating was upgraded by Credit Suisse to "Outperform" on Thursday, August 24. Oppenheimer maintained Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) rating on Monday, March 28. The stock of Portola Pharmaceuticals, Inc. The rating was downgraded by Citigroup to "Neutral" on Friday, August 19. On Friday, August 4 the stock rating was maintained by Oppenheimer with "Buy". Oppenheimer maintained Portola Pharmaceuticals, Inc. The rating was maintained by Cowen & Co on Wednesday, August 5 with "Buy". (NASDAQ:XLNX) earned "Buy" rating by KeyBanc Capital Markets on Wednesday, September 6. The firm earned "Hold" rating on Tuesday, August 2 by Canaccord Genuity.

Since December 15, 2017, it had 0 buys, and 1 insider sale for $563,950 activity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



Latest news

Evercore ISI Initiates Coverage on Becton Dickinson and (BDX)
Northern Trust Corp decreased Zimmer Biomet Hldgs Inc (ZMH) stake by 77,943 shares to 3.93 million valued at $460.44M in 2017Q3. Stellar Capital Management Ltd Liability Co holds 1.21% in Occidental Petroleum Corporation (NYSE:OXY) or 26,773 shares.

Have no suspicion on death, don't harass us, says Justice Loya son
We have no suspicion on his death. "There is no controversy, no need of politicising the issue". "This is a tragic event. Lawyer Ameet Naik reiterated Loya's view at the press conference on Sunday.

Kane: Levy ready to play hardball amid Real Madrid interest
He said: "I'm 100 per cent confident that every player we want to keep will be playing for Tottenham Hotspur next season". The Belgian defender is now tied to Spurs until 2019 but has been stalling for the previous year .

Discovery Communications Inc. (DISCB) Upgraded by Zacks Investment Research to Hold
The active investment managers in our partner's database now own: 204.44 million shares, up from 195.01 million shares in 2017Q2. The insider WARGO J DAVID bought $1.86M. (Nasdaq: "DISCA) to Ring the Nasdaq Stock Market ..." on December 22, 2017.

Chevron (CVX) Earns "Buy" Rating from Scotiabank
The broad Regional - Midwest Banks industry has an average P/S ratio of 6.33, which is significantly worse than the sector's 6.31. Greatmark Investment Partners Inc. increased its stake in shares of Chevron Corporation by 0.5% in the third quarter.

Other news